Kidney transplant study tests safer antiviral option
NCT ID NCT07294547
First seen Jan 11, 2026 · Last updated May 10, 2026 · Updated 21 times
Summary
This study tests whether valacyclovir works as well as valganciclovir for preventing CMV and EBV infections in kidney transplant patients. Both drugs are used to stop these viruses from becoming active after transplant. Valacyclovir may have fewer side effects, especially less bone marrow suppression, which is common with valganciclovir. The study will enroll 80 kidney transplant recipients and follow them to compare infection rates and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.